Given an increasing use of DPP-4 inhibitors to treat patients with T2DM in the real-world setting, potential pancreatitis risk has been of concern because of its consequent pharmacological mechanism of the pancreas [7, 21]. This evidence concerns the gene DPP4 and pancreatitis.